KAT8 and acute myeloid leukemia: Themost promising inhibitors in terms of KAT8 inhibitory potency andisoform selectivity were then assessed in a panel of cancer cell lines,including the NSCLC cells H1299, A549, and NCI-H460, the MCF-7 breastcancer cell line, the AML cell lines U937 and THP-1, the colorectalcarcinoma (CRC) cell lines HT29 and HCT116, and the HeLa cervicalcancer cells.